Commentary
Commentary
California’s lawsuit against energy companies will increase greenhouse gas emissions
This fall the San Francisco Superior Court is holding a hearing on California’s lawsuit against American energy companies. The lawsuit alleges that these private U.S. companies misled the public about greenhouse gases’ impact and are responsible for covering the costs associated with climate disasters. But California and the federal government ...
Commentary
Trump’s Medicaid reform is moral and necessary
Among the most contentious provisions in the One Big Beautiful Bill Act, which President Donald Trump signed into law on July 4, are its Medicaid work requirements. Starting in 2027, able-bodied, working-age Medicaid beneficiaries enrolled through Obamacare’s expansion of the program must spend at least 80 hours a month on ...
Commentary
Thanks to Obamacare, Insurance Fraud Irresistible
Something strange is afoot on the Obamacare exchanges. According to a new study by the Paragon Health Institute, an astounding number of patients with premium-free exchange plans filed no claims whatsoever last year. It’s possible that none of these individuals required medical care in 2024. Read the op-ed here.
Commentary
It’s Time To Let The Electric Vehicle Industry Grow Up
The U.S. has been subsidizing electric vehicles (EVs) since 2009 and hybrid vehicles for even longer. Recent Congressional actions have substantially changed this policy. As part of the reconciliation package, Congress rolled back the $7,500 federal EV tax credit ($4,000 credit for used EVs) as well as the EV battery ...
Commentary
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Commentary
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
Commentary
Trump Embraces Disastrous Most Favored Nation Drug Pricing
President Donald Trump gave American drug companies an ultimatum last month. Either they agree to adopt foreign-style price controls, or the administration “will deploy every tool in [its] arsenal” to do it for them. More specifically, the president asked drug firms to base U.S. drug prices for a given drug ...
Business & Economics
Using The Government To Crush Competitors Harms Fans And The Economy
Cronyism and industrial policy are thriving to the detriment of our economic vibrancy. Consider that between 1960 and 2007 – right before the Great Recession – the economy expanded by more than 3% annually. Recessions happened, of course, but the economy always recovered the lost ground. Read the op-ed here.
Commentary
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
Commentary
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
California’s lawsuit against energy companies will increase greenhouse gas emissions
This fall the San Francisco Superior Court is holding a hearing on California’s lawsuit against American energy companies. The lawsuit alleges that these private U.S. companies misled the public about greenhouse gases’ impact and are responsible for covering the costs associated with climate disasters. But California and the federal government ...
Trump’s Medicaid reform is moral and necessary
Among the most contentious provisions in the One Big Beautiful Bill Act, which President Donald Trump signed into law on July 4, are its Medicaid work requirements. Starting in 2027, able-bodied, working-age Medicaid beneficiaries enrolled through Obamacare’s expansion of the program must spend at least 80 hours a month on ...
Thanks to Obamacare, Insurance Fraud Irresistible
Something strange is afoot on the Obamacare exchanges. According to a new study by the Paragon Health Institute, an astounding number of patients with premium-free exchange plans filed no claims whatsoever last year. It’s possible that none of these individuals required medical care in 2024. Read the op-ed here.
It’s Time To Let The Electric Vehicle Industry Grow Up
The U.S. has been subsidizing electric vehicles (EVs) since 2009 and hybrid vehicles for even longer. Recent Congressional actions have substantially changed this policy. As part of the reconciliation package, Congress rolled back the $7,500 federal EV tax credit ($4,000 credit for used EVs) as well as the EV battery ...
Time To Crack Down On The Knock-Off Weight-Loss Drug Trade
Wegovy, Zepbound, and other GLP-1 agonists have given Americans an extraordinary new tool for losing weight and improving their health. But they’ve also given rise to a dangerous new public health threat—counterfeit medicines. In a rush to capitalize on the popularity of these drugs, a number of third-party telehealth firms ...
Should the Government Control Drug Prices? No…
In a May 12 executive order, President Trump announced a “most favored nation” policy that intends to lower prescription drug prices. Among other things, the order directed the Secretary of Health and Human Services to “communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices . . . in line ...
Trump Embraces Disastrous Most Favored Nation Drug Pricing
President Donald Trump gave American drug companies an ultimatum last month. Either they agree to adopt foreign-style price controls, or the administration “will deploy every tool in [its] arsenal” to do it for them. More specifically, the president asked drug firms to base U.S. drug prices for a given drug ...
Using The Government To Crush Competitors Harms Fans And The Economy
Cronyism and industrial policy are thriving to the detriment of our economic vibrancy. Consider that between 1960 and 2007 – right before the Great Recession – the economy expanded by more than 3% annually. Recessions happened, of course, but the economy always recovered the lost ground. Read the op-ed here.
Tariffs Won’t Secure Our Drug Supply Chain—They’ll Break It
The Trump administration is considering massive “Section 232” tariffs on imported medicines from key U.S. allies, including the European Union, the United Kingdom, Switzerland, Japan, and South Korea. While tariffs on some countries, such as EU member states, could be capped at 15%, other tariffs could reportedly be set as ...
The New Medicine Tariffs Are a Prescription for Disaster
President Trump has recently struck trade agreements with the European Union and Japan. Both deals will impose a 15 percent tariff on imported prescription drugs and active pharmaceutical ingredients. White House officials believe these tariffs will benefit Americans by nudging pharmaceutical companies to relocate their manufacturing operations stateside in order ...
